
Please try another search
Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment. The company has collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Name | Age | Since | Title |
---|---|---|---|
Wendyl D’Souza | - | 2018 | Member of Medical Advisory Board |
Ross Grant Thomas Walker | - | 2016 | Chairman of Strategic Advisory Board |
Uri Kramer | - | 2016 | Member of Strategic Advisory Board |
Daniel Robinson | - | 2023 | Non-Executive Independent Director |
Shlomo Sadoun | - | 2024 | Member of Advisory Board |
Gary Hermon | - | 2025 | Non-Executive Director |
Roby Reuven Zomer | 45 | 2016 | Co-Founder, CEO & Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review